Drug Database
ZO

zolpidem tartrate (Stilnox CR / FK199B / Stilnoxium)

✓ Approved

Astellas Pharma · GABRA1 · 小分子

什么是 zolpidem tartrate?

zolpidem tartrate 是一种小分子,由Astellas Pharma研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Stilnox CR, FK199B, Stilnoxium
公司Astellas Pharma
药物类别小分子
分子靶点GABRA1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

zolpidem tartrate 作用于 1 个分子靶点:

GABRA1gamma-aminobutyric acid type A receptor alpha1 subunit (DEE19, ECA4)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

zolpidem tartrate 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Psychiatric disordersInsomnia✓ Approved

相关研究文献

PubMedBrain injury2026-11-19

Continuous multimodal neuromonitoring of zolpidem-induced paradoxical awakening in chronic incomplete locked-in syndrome: ventral pontine deafferentation, cross-modal complementarity, and cardio-cortical dissociation.

Machado Calixto C, Rodriguez-Rojas Rafael R, Sanchez Jose Jesus JJ, Mualem Raed R

Zolpidem paradoxically restores responsiveness in select disorders of consciousness (DOC) cases, yet real-time electrophysiological and autonomic dynamics across the pharmacodynamic trajectory remain uncharacterized in incomplete locked-in syndrome (LIS). A 52.18-min multimodal recording tracked baseline, enteral zolpidem administration (min 22.39), absorption, corticomotor peak, and plateau in a 42-year-old male with chronic LIS from pontine infarction. Analytics included continuous qEEG (0.5-70 Hz), microstates (Classes A-D), beta-band weighted Phase Lag Index (wPLI) connectomics, heart rate variability (HRV), and heartbeat‑evoked responses (HER). Baseline deafferentation showed severe theta slowing (48.36 ± 4.14%) and phase hypersynchrony. Following enteral administration, the following changes were observed: 1. viscero-cortical dissociation: Infusion triggered an immediate HRV VHF surge (>80%) while the cortex remained quiescent for 14.1 min. 2. Corticomotor consolidation: Between min 36.5-46.0, relative beta surged (+266.89%) while theta dropped (-30.74%). Microstates accelerated into frontocentral Classes C/D, and connectomics demonstrated long-range edge pruning with selective frontocentral recruitment (wPLI > 0.40). 3. Interoceptive gating: During peak beta emergence, cardio-cortical communication collapsed; evoked global variance profile dropped > 60% (1.03 to 0.22 µV) alongside frontocentral dipole suppression. Paradoxical awakening is a coordinated multisystem process. Zolpidem disinhibits spared corticomotor networks while filtering ascending visceral baro-afferents, enabling an outward-facing behavioral state decoupled from internal interoception.

PMID 43052692
阅读全文 →
PubMedChemistry (Weinheim an der Bergstrasse, Germany)2026-11-19

Heteroatom-Synergistic Modulation of Emission Bandwidth in Multi-Resonance Thermally Activated Delayed Fluorescence Molecules.

Cai Wanlin W, Zhong Cheng C, Ma Zi-Wei ZW, Cai Zhuan-Yun ZY et al.

Multi-resonance thermally activated delayed fluorescence (MR-TADF) molecules are promising emitters for high-end displays offering narrowband emission with high color purity. This advantage is related to heteroatom-enabled resonance effects that reduce the reorganization energy, an effective descriptor of the full width at half-maximum (FWHM). Here, we elucidate the physicochemical origin of the color purity differences arising from heteroatom synergy in two representative MR-TADF series. In the B-centered MR-TADF molecules, the B-π-S analogues exhibit smaller FWHM (higher color purity) than the corresponding B-π-O analogues, owing to the decreased bond-length (BL) contribution to the reorganization energy. Conversely, in the N-centered MR-TADF molecules, the N-π-S analogues exhibit larger FWHM (lower color purity) than the corresponding N-π-O analogues, which is associated with the increased dihedral-angle (DA) contribution to the reorganization energy. Building on the above insights, we suggest two possible molecular-design approaches to enhance the color purity of MR-TADF molecules: (i) engineering the frontier-orbital distribution to suppress BL alterations; (ii) mitigating the orbital antibonding interaction to suppress DA alterations. To assess these approaches, four N-centered MR-TADF molecules were designed and computationally evaluated. The reductions in calculated reorganization energy and FWHM further support the proposed molecular-design approaches, highlighting their potential for improving the color purity of MR-TADF emitters.

PMID 43053311
阅读全文 →
PubMedMagnetic resonance in medicine2026-11-19

Rigid Motion Estimation Using Accelerated Coordinate Descent (REACT) for MR Imaging.

Jang Kwang Eun KE, Nishimura Dwight G DG

To develop a computationally viable autofocus method for estimating 3D rigid motion in MR imaging. The proposed method, REACT, assumes a piecewise-constant motion trajectory and estimates the rigid motion parameters of individual temporal segments by optimizing an image-quality metric. Coordinate descent is adopted to decompose the high-dimensional optimization problem into a series of subproblems, each updating the motion parameters of a single temporal segment. The cost function of each subproblem is assumed to be approximately locally convex under suitable acquisition conditions. Each subproblem is then solved using a derivative-free solver, thereby avoiding an exhaustive grid search. Numerical simulations investigated the local convexity assumption and data acquisition requirements. REACT was evaluated for respiratory motion correction on in vivo free-breathing coronary MR angiography datasets. Coronary artery sharpness was quantified using unbounded image edge profile acutance (u-IEPA). In numerical simulations, the objective surfaces of the subproblems were approximately locally convex when the current motion estimate was sufficiently close to the desired solution, and REACT required the data collected within each temporal segment to be sufficiently distributed across k -space. In the in vivo study, REACT yielded higher u-IEPA for both the left anterior descending artery (LAD) and the right coronary artery than did a conventional translational motion-estimation method using image-based navigators. REACT also yielded higher u-IEPA for the LAD than did a conventional autofocus nonrigid motion correction method. This study demonstrates the feasibility of coordinate descent for autofocus motion correction in MR imaging.

PMID 43053177
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Anaesthetic strategy and functional outcomes during contemporary transcatheter mitral edge-to-edge repair: a matched comparison of dexmedetomidine-based conscious sedation versus general anaesthesia.

Rroku Andi A, Kempe Theodor T, Thevathasan Tharusan T, Kasner Mario M et al.

Transcatheter mitral edge-to-edge repair (M-TEER) is an established therapy for severe mitral regurgitation (MR) in patients at increased surgical risk. While procedures are commonly performed under general anaesthesia (GA), dexmedetomidine-based conscious sedation (DCS) may preserve physiological haemodynamics and improve procedural efficiency. Comparative data remain limited. To compare procedural effectiveness, efficiency and safety of M-TEER performed under GA versus DCS. In this retrospective observational study, patients undergoing M-TEER under anaesthesiologist-guided DCS or GA were analysed using propensity score matching to adjust for baseline differences. The primary endpoint was device effectiveness, defined as successful implantation with MR reduction to ≤2+ post-procedure and sustained at discharge. Procedural duration was analysed as a secondary workflow endpoint. The main safety endpoint was a composite of all-cause death, stroke, cardiac structural complications, cardiogenic shock, acute kidney injury requiring renal replacement therapy, or moderate/severe bleeding according to Mitral Valve Academic Research Consortium criteria. Ninety-seven patients were included (DCS 37; GA 60). Device implantation success was achieved in 98.9% of procedures. Immediate device effectiveness was high and comparable between strategies (100 vs 98.3%; P = 1.0). Procedural duration was shorter with DCS [84 (interquartile range 70.5-111.5) vs 102.5 (78-144) min; P = .019]. In matched analysis (36 pairs), fluoroscopy time, radiation dose, and residual MR at discharge (MR ≤1: 86.1 vs 83.3%; P = .743) were similar. The composite safety endpoint did not differ significantly (P = .436), and no surgical conversions occurred. Dexmedetomidine-based conscious sedation provided procedural effectiveness and safety comparable to GA while improving procedural efficiency. These findings support an individualized anaesthetic strategy and warrant prospective evaluation in contemporary M-TEER practice.

PMID 43053853
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Changes in loop diuretic use following mitral valve surgery for mitral regurgitation according to age: a nationwide cohort study.

Melchior Simon E SE, Schöps Liv B LB, Petersen Jeppe K JK, Carranza Christian L CL et al.

Loop diuretic use (LDU) may provide complementary information on post-operative heart failure (HF) burden after mitral valve surgery (MVS). We investigated changes in LDU before and after MVS for mitral regurgitation (MR) and assessed post-operative HF admission according to age. Using Danish nationwide registries, we identified patients aged ≥18 years discharged after first-time MVS for MR between 1996 and 2022. LDU was assessed from redeemed prescriptions before surgery and at post-operative landmarks. HF admission within 5 years was estimated with death as a competing risk. Among 6840 patients, LDU was 46.2% before surgery and declined among survivors to 27.0% at 12-15 months and 23.7% at 36-39 months. Pre-operative use was more frequent with increasing age, ranging from 27.9% in patients aged 18-49 years to 64.3% in those aged ≥80 years. Postoperatively, LDU remained common, ranging from 13.5% to 41.6% at 12-15 months and from 11.9% to 35.4% at 36-39 months across age groups. The 5-year cumulative incidence of HF admission was 20.9% (95% CI: 20.0-22.0%) overall and increased across age groups, from 13.9% to 27.4%. Pre-operative LDU was associated with higher 5-year mortality irrespective of recorded HF status. LDU declined after MVS for MR but remained common, particularly among older patients, and showed an age-related pattern consistent with hospital admission for HF.

PMID 43053869
阅读全文 →
PubMedEuropean heart journal. Valvular and structural heart disease2026-11-19

Prognostic impact of tricuspid regurgitation improvement after transcatheter mitral valve replacement: results from an international multicentre registry.

von der Heide Ina I, Scotti Andrea A, Coisne Augustin A, Strotmann Lena L et al.

Tricuspid regurgitation (TR) frequently coincides with severe mitral regurgitation (MR). Transcatheter mitral valve replacement (TMVR) effectively eliminates MR and may secondarily affect TR severity. This study aimed to assess incidence and prognostic value of TR improvement after TMVR using data from an international multicentre registry. Patients with symptomatic MR and baseline TR undergoing TMVR from the CHoice of OptImal transCatheter trEatment for Mitral Insufficiency international multicentre registry were analysed. Tricuspid regurgitation improvement was defined as a ≥1-grade TR reduction at discharge. The primary endpoint was all-cause mortality or heart failure (HF) hospitalization at 1 year. Stepwise Cox regression was performed to assess the adjusted prognostic impact of TR improvement. Among 309 patients (median age 77 years), TR improvement occurred in 33.0% after TMVR. Patients with TR improvement were younger, had higher European System for Cardiac Operative Risk Evaluation II, less coronary artery disease, and lower baseline tricuspid annular plane systolic excursion. Mitral regurgitation was durably eliminated in most patients, irrespective of TR evolution. At 1 year, there was no statistically significant difference in all-cause mortality or HF hospitalization between patients with and without TR improvement (27.0% vs 36.9%; P = .14). Following stepwise Cox regression, TR improvement was an independent predictor of all-cause mortality or HF hospitalization 1 year after TMVR (hazard ratio 0.45, 95% confidence interval 0.23-0.88; P = .02). TR improvement occurs frequently following TMVR and is associated with favourable 1-year outcomes. These results support the clinical relevance of concomitant TR and the systematic assessment of TR after TMVR.

PMID 43053866
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多zolpidem tartrate